|
Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease
|
Jan 2018
|
Biology of Blood and Marrow Transportation
|
graft versus host disease (GVHD)
|
|
Diagnosis of paroxysmal nocturnal hemoglobinuria in peripheral blood and bone marrow with six-color flow cytometry.
|
Feb 2012
|
Biomark Med
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes
|
Oct 2016
|
Biomed Pharmacother
|
myelodysplastic syndromes (MDS)
|
|
Genetics of Progression From MDS to Secondary Leukemia
|
May 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Paroxysmal nocturnal hemoglobinuria
|
Sep 2014
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia
|
May 2017
|
Blood
|
acute myeloid leukemia (AML)
|
|
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure
|
Jun 2016
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
|
Dec 2015
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)
|
Jul 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
How we treat higher-risk myelodysplastic syndromes
|
Dec 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
